EU approves Dr Reddy's osteoporosis treatment

Business Nov 24, 2025

Dr. Reddy's just got the green light from the European Commission for AVT03, a new biosimilar medicine that helps with bone health.
It's modeled after Prolia and Xgeva—drugs used to treat osteoporosis and prevent serious bone problems in people with cancer.
This approval means more options for patients across Europe who need reliable treatments for fragile bones.

The bigger picture

AVT03 is now cleared for use in all EU and EEA countries, including places like Iceland and Norway.
The drug comes from a partnership between Dr. Reddy's and Alvotech—Alvotech develops and manufactures it, while Dr. Reddy's handles getting it to market in big regions like Europe and the US.
After the news dropped, Dr. Reddy's shares dipped slightly.